[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586261":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":75,"collaborators":11,"id":77,"slug":11,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":100,"whyStopped":11,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Indira IVF Hospital Pvt Ltd","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","ACTIVE_COMPARATOR",null,[13],"Drug: GnRH agonist downregulation",{"label":15,"type":10,"description":11,"interventionNames":16},"Group B",[17],"Drug: GnRH agonist and Letrozole",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","GnRH agonist downregulation","Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"GnRH agonist and Letrozole","Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Taruna Jhamb, MD","CONTACT","+91 9799035674","centerhead.udaipur@indiraivf.in",[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Indira IVF Pvt Hospital","Udaipur","Rajasthan","313001","India",{"type":42,"coordinates":43},"Point",[44,45],73.71346,24.58584,{"lat":45,"lon":44},[48,51,53,56,57,59,61,63,65,67,69,71,73],{"name":49,"role":31,"phone":11,"phoneExt":11,"email":50},"Vipin Chandra, DGO","drvipinchandra@indiraivf.in",{"name":30,"role":52,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":54,"role":55,"phone":11,"phoneExt":11,"email":11},"Peter Humaidan, DMSc","SUB_INVESTIGATOR",{"name":49,"role":55,"phone":11,"phoneExt":11,"email":11},{"name":58,"role":55,"phone":11,"phoneExt":11,"email":11},"Snehadarshani Karnath, MD",{"name":60,"role":55,"phone":11,"phoneExt":11,"email":11},"Yasha Pandey, MD",{"name":62,"role":55,"phone":11,"phoneExt":11,"email":11},"Akanksha Jangid, MD",{"name":64,"role":55,"phone":11,"phoneExt":11,"email":11},"Pawan Yadav, MD",{"name":66,"role":55,"phone":11,"phoneExt":11,"email":11},"Pooja Shinde, DNB",{"name":68,"role":55,"phone":11,"phoneExt":11,"email":11},"Nisha Tiwari, DNB",{"name":70,"role":55,"phone":11,"phoneExt":11,"email":11},"Tanu Batra, DNB",{"name":72,"role":55,"phone":11,"phoneExt":11,"email":11},"Amol Lunkad, MD",{"name":74,"role":55,"phone":11,"phoneExt":11,"email":11},"Rinoy Sreedharan, MD",{"type":76,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100586261",false,"NCT06913075","FET in Adenomyosis","Is GnRH Agonist Plus Letrozole a Better Choice Than GnRH Agonist Alone in Adenomyosis Cases Undergoing Frozen Embryo Transfer?","ADY","Inclusion Criteria:\n\nDiagnosis of adenomyosis confirmed via transvaginal ultrasound as per MUSA criteria History of infertility requiring frozen embryo transfer (FET). Availability of at least one good-quality frozen embryo for transfer\n\nExclusion Criteria:\n\nBMI ≥ 30 kg\u002Fm2 Presence of endocrine disorders; (uncontrolled diabetes mellitus, \u002F hyperprolactinemia, thyroid dysfunction, Congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome Previous major uterine surgery Gestational carrier Fertility preservation","FEMALE","21 Years","42 Years",{"count":88,"type":89},700,"ESTIMATED","INTERVENTIONAL",[92],"NA","Purpose of the Study:\n\nTo compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET).\n\nResearch Question:\n\nIs the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET?\n\nHypothesis:\n\nNull Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET.\n\nStudy Outcomes:\n\nPrimary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.",[95],"Adenomyosis",[97,95,98,99],"Frozen embryo transfer","ongoing pregnancy rate","live birth rate","NOT_YET_RECRUITING","2026-01-23",{"date":103,"type":104},"2026-01-26","ACTUAL",{"date":106,"type":89},"2026-06-25",{"date":108,"type":89},"2026-12-23",{"name":5,"class":6},1]